Streetbeat News

Revenues

ULY

Urgently (NASDAQ:ULY) reported a Q4 EPS of $11.95 with sales reaching $45.05M, marking a 13.31% decrease from $51.97M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:04 pm

NTDOY

TTWO

WBD

Circana analyst Mat Piscatella provided a mixed outlook for the gaming industry, highlighting the significant impact of Take-Two Interactive's upcoming Grand Theft Auto 6 (GTA 6) release. He predicts a potential decline in consumer spending of 2% to 10% due to uncertainties, including the lack of major game releases and hardware schedule disruptions. Piscatella also discussed the industry's shift from physical to digital media and the absence of a new Nintendo hardware release this year. Despite short-term challenges, he remains cautiously optimistic about the industry's return to growth.

Portfolio Pulse from Franca Quarneti

March 14, 2024 | 7:10 pm

ACB

Recent developments in cannabis legislation and market dynamics across Europe include France excluding cannabis flower from its medical marijuana program, the UK grappling with a booming illegal cannabis market estimated at $3.3 billion annually, and Germany facing calls to delay cannabis legalization. Aurora Cannabis (NASDAQ:ACB), a major player in the cannabis industry, has expressed concerns over the uncertainty caused by potential delays in Germany's cannabis legalization, emphasizing the need for legal clarity to ensure investment and planning security.

Portfolio Pulse from Nina Zdinjak

March 14, 2024 | 6:53 pm

PFE

ZLAB

CStone Pharmaceuticals faced a significant stock price drop after being removed from the Stock Connect list, which allows mainland investors to trade Hong Kong stocks. The removal followed its exclusion from the Hang Seng index due to its market value falling below the eligibility level. CEO Jason Yang has shown confidence in the company by increasing his stake. CStone has shifted focus to R&D and licensed out several products, including sugemalimab to Pfizer. Other companies like Brii Biosciences, Jacobio Pharmaceuticals, and Yonghe Medical also suffered stock price declines after being dropped from the Stock Connect list.

Portfolio Pulse from The Bamboo Works

March 14, 2024 | 6:48 pm

CMI

Truist Securities analyst Jamie Cook initiated coverage on Cummins Inc (NYSE:CMI) with a Hold rating and a $303 price target. Cummins, a global diesel engine manufacturer, was recently fined $2 billion for emission issues related to Dodge Ram trucks. The fine impacts its capital allocation, directing free cash towards debt payment from the Meritor acquisition and rebuilding its balance sheet, rather than returning cash to shareholders. Despite this, Cummins is expected to see growth in 2025 and 2026 due to a pre-buy ahead of the 2027 emissions change for trucks. Cummins has also gained share in the medium-duty overseas market, potentially adding at least $2.50 in EPS Power. The $303 price target is based on 9X EV/EBITDA and 16X P/E multiple on 2025 estimates, discounted back. CMI shares dropped 2.66% to $263.07.

Portfolio Pulse from Shivani Kumaresan

March 14, 2024 | 6:39 pm

GNS

Genius Group has completed its merger with FatBrain AI, following NYSE approval. The all-stock transaction includes AI software assets, customer relationships, and specific operations of FatBrain AI. This merger is expected to increase Genius Group's 2023 pro forma revenue guidance by approximately 150% to an estimated $76 million to $80 million, and its pro forma net profit guidance by $4 million to $7 million to $9 million.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 6:12 pm

SUM

Summit Materials (NYSE:SUM) received 11 analyst ratings in the last three months, showing a diverse range of perspectives from bullish to bearish. The average 12-month price target for SUM is $43.73, marking a 7.02% increase from the previous target of $40.86. Analysts from firms like RBC Capital, Barclays, and Goldman Sachs have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Summit Materials, engaged in the production and sale of construction materials, has shown a positive revenue trend with a growth rate of 19.53% as of December 31, 2023, but faces challenges in profitability, debt management, and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 6:01 pm

PWR

7 analysts have recently shared their evaluations of Quanta Services (NYSE:PWR), with opinions ranging from bullish to bearish. The average 12-month price target for PWR has been raised to $249.71, indicating a 13.5% increase from the previous target of $220.00. Analysts from firms including Truist Securities, DA Davidson, Goldman Sachs, Stifel, Evercore ISI Group, and Citigroup have updated their ratings and price targets, reflecting a positive outlook on the company's performance. Quanta Services has shown strong financial indicators such as a 30.96% revenue growth rate, a net margin of 3.65%, and an ROE of 3.44%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 6:00 pm

SKIN

Analyst ratings for Beauty Health (NASDAQ:SKIN) have been updated, with 5 analysts providing evaluations in the last three months. The average 12-month price target for SKIN has been raised to $3.6, a 38.46% increase from the previous target of $2.60. Analysts' sentiments have shifted slightly towards a more neutral stance, with recent ratings indicating 4 indifferent and 1 somewhat bearish outlooks. Beauty Health's financial performance shows a decline in revenue growth and challenges in ROE, but a strong net margin and ROA. The company's debt-to-equity ratio is higher than the industry average, indicating a reliance on borrowed funds.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 6:00 pm

HNST

Honest Co (NASDAQ:HNST) has been analyzed by 5 analysts, showing a shift towards a more neutral stance in the last quarter with an average 12-month price target of $4.15, up 58.4% from the previous target. The company's financial health appears strong, with positive revenue growth, above-average net margin, ROE, and ROA, and a low debt-to-equity ratio. Analysts have adjusted their ratings and price targets based on recent developments, indicating a cautiously optimistic outlook for HNST.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:01 pm